These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22674382)

  • 1. Down-regulation of hematopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid leukemia.
    Yang H; Liang H; Yan JS; Tao R; Hao SG; Ma LY
    Int J Hematol; 2012 Jul; 96(1):65-73. PubMed ID: 22674382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
    Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.
    Albajar M; Gutierrez P; Richard C; Rosa-Garrido M; Gómez-Casares MT; Steegmann JL; León J; Delgado MD
    Cancer Lett; 2008 Nov; 270(2):328-36. PubMed ID: 18635311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3.
    Yang MY; Chang JG; Lin PM; Tang KP; Chen YH; Lin HY; Liu TC; Hsiao HH; Liu YC; Lin SF
    Cancer Sci; 2006 Dec; 97(12):1298-307. PubMed ID: 16999817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
    Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
    Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
    J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JunB gene expression is inactivated by methylation in chronic myeloid leukemia.
    Yang MY; Liu TC; Chang JG; Lin PM; Lin SF
    Blood; 2003 Apr; 101(8):3205-11. PubMed ID: 12506033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
    Vatanmakanian M; Tavallaie M; Ghadami S
    Cell Commun Signal; 2019 Apr; 17(1):38. PubMed ID: 31014357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metallothionein-1 isoforms and vimentin are direct PU.1 downstream target genes in leukemia cells.
    Imoto A; Okada M; Okazaki T; Kitasato H; Harigae H; Takahashi S
    J Biol Chem; 2010 Apr; 285(14):10300-9. PubMed ID: 20139074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
    Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
    San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
    Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation status of CEBPA gene promoter in chronic myeloid leukemia.
    Annamaneni S; Kagita S; Gorre M; Digumarti RR; Satti V; Battini MR
    Hematology; 2014 Jan; 19(1):42-4. PubMed ID: 23541085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.
    Jelinek J; Gharibyan V; Estecio MR; Kondo K; He R; Chung W; Lu Y; Zhang N; Liang S; Kantarjian HM; Cortes JE; Issa JP
    PLoS One; 2011; 6(7):e22110. PubMed ID: 21760961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methyltransferase 1 mediated aberrant methylation and silencing of SHP-1 gene in chronic myelogenous leukemia cells.
    Li Y; Liu X; Guo X; Liu X; Luo J
    Leuk Res; 2017 Jul; 58():9-13. PubMed ID: 28376405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
    Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
    Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPX3 promoter is methylated in chronic myeloid leukemia.
    Yao DM; Zhou JD; Zhang YY; Yang L; Wen XM; Yang J; Guo H; Chen Q; Lin J; Qian J
    Int J Clin Exp Pathol; 2015; 8(6):6450-7. PubMed ID: 26261521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon induces up-regulation of Spi-1/PU.1 in human leukemia K562 cells.
    Gutiérrez P; Delgado MD; Richard C; Moreau-Gachelin F; León J
    Biochem Biophys Res Commun; 1997 Nov; 240(3):862-8. PubMed ID: 9398659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research on epigenetic mechanism of SFRP2 in advanced chronic myeloid leukemia.
    Li Z; Luo J
    Biochem Biophys Res Commun; 2018 Jun; 501(1):64-72. PubMed ID: 29704505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region.
    Ortmann CA; Burchert A; Hölzle K; Nitsche A; Wittig B; Neubauer A; Schmidt M
    Nucleic Acids Res; 2005; 33(21):6895-905. PubMed ID: 16396836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
    Fajkusová L; Fajkus J; Polácková K; Fulnecek J; Dvoráková D; Krahulcová E
    Blood Cells Mol Dis; 2000 Jun; 26(3):193-204. PubMed ID: 10950939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.